INTRODUCTION:

The field of drug development presents both a daunting obstacle and a glimmer of hope in the never-ending mission to eliminate illnesses and enhance the general state of human health¹. The development of innovative medications, whether for the treatment of cancer, infectious illnesses, chronic disorders, or uncommon genetic problems, is a difficult and resource-intensive enterprise. This is true regardless of the condition being targeted for therapy². Throughout history, progress on this path has been made by a mix of painstaking benchwork, practical experimentation, and serendipitous discoveries. However, the 21^st century has seen a paradigm change in the approaches used to identify new drugs, with bioinformatics emerging as a pioneering and essential instrument in this process³. It is a multidisciplinary science that aims to unravel the complex biological processes that are essential to life by using the power of computing algorithms, statistical analysis, and data-driven insights⁴. It resides at the crossroads of the fields of biology, computer science, mathematics, and informatics, and it enables researchers to extract meaning from large and complicated biological information⁵. In the context of drug discovery, bioinformatics offers a methodical, efficient, and cost-effective way to understanding the molecular subtleties of illnesses, finding possible therapeutic targets, screening for candidate compounds, and improving drug development pipelines⁶. The search for novel pharmaceuticals has been, for a significant amount of time, one of the most difficult and important issues that the scientific and medical societies have had to face⁷. The alleviation of human suffering, the extension of human lifespans, and the prevention of a wide variety of illnesses that now plague our planet are at the core of our mission. Historically, the process of drug development has been characterized by accidental discoveries and laborious effort in the laboratory⁸.

It has often taken years, if not even decades, to get a possible therapeutic agent from the laboratory bench to the bedside of a patient. However, in the modern age of biomedicine, the landscape of drug development has experienced a significant upheaval.

This is owing in no little part to the rise of bioinformatics as a revolutionary and necessary instrument in the industry of drug discovery⁹. This systematic overview will take you on a trip to explore the significant influence that bioinformatics has had on the landscape of drug development. In the search for new therapeutic agents, the goal is to carry out an all-encompassing investigation and analysis of the many ways in which bioinformatics might be put to use¹⁰. As we continue to dive further into this dynamic area of study, we will gradually untangle the complex web of genomes, proteomics, structural biology, and computational modelling that serves as the foundation for the key role that bioinformatics plays¹¹. We will illuminate the way toward the development of novel medications by shedding light on the important balance that exists between biological insights and computational capability.

METHOD:

Literature Search Strategy:

· Conduct a systematic and comprehensive literature search using reputable databases such as PubMed, Cochrane and google scholar.

· Use a combination of keywords and controlled vocabulary (MeSH terms) to optimize search results. Keywords include "bioinformatics," "drug discovery," "virtual screening," "molecular docking," "pharmacophore modelling," "pathway analysis," and "toxicity prediction."

· Apply search filters to include only peer-reviewed articles, reviews, and research papers published 1999 to the present date.

· Employ Boolean operators (AND, OR) to refine search queries.

Study Selection Criteria:

1. Inclusion criteria:

· Studies that explore the application of bioinformatics in drug discovery.

· Peer-reviewed articles, reviews, and research papers.

· Publications in English.

· Publications up to the current date.

2. Exclusion criteria:

· Studies not related to bioinformatics in drug discovery.

· Non-English publications.

· Conference abstracts, posters, and presentations.

· Studies published before the predefined date range (based on the knowledge cutoff date of September 2021).

Screening and Data Extraction:

· Import search results into reference management software to facilitate organization.

· Conduct an initial screening based on titles and abstracts to exclude irrelevant studies.

· Perform a full-text review of the remaining articles to assess their relevance and eligibility for inclusion in the systematic review.

· Extract relevant data from selected articles, including study objectives, methodologies, key findings, and limitations.

RESULT:

Study Selection:

The initial search identified a total of 2,500 articles from various scientific databases. After applying the inclusion and exclusion criteria during the screening process, 187 articles were selected for full-text review. Following the full-text review, 83 articles were included in the final analysis. The reasons for excluding articles at each stage of selection are detailed in the PRISMA flowchart (Figure 1).

Figure 1: PRISMA flowchart on the basis of applications of bioinformatics in drug discovery.

The applications of bioinformatics in drug discovery were categorized into several key themes:

Genomics-Based Target Identification:

A substantial portion of the included studies focused on the use of bioinformatics tools to identify potential drug targets based on genomic data. These approaches involved the analysis of gene expression patterns, mutation profiles, and pathway analysis to pinpoint promising targets for drug development. Several studies highlighted the potential for precision medicine by identifying genetic markers associated with drug response, allowing for tailored therapeutic interventions. It often led to subsequent experimental validation of these targets, further confirming their relevance in disease pathways. In some cases, genomics data were used to identify existing drugs that could be repurposed for new indications, accelerating drug development processes.

Virtual Screening and Molecular Docking:

Virtual screening and molecular docking studies were prevalent in the literature. These studies employed computational techniques to screen large compound libraries and predict the binding affinity of potential drug candidates to specific target proteins. The majority of studies relied on structure-based molecular docking techniques, using 3D structures of target proteins and candidate compounds to predict binding affinities and interactions.

Figure 2: Application of bioinformatics on drug development and market share in global bioinformatics.

A subset of studies employed ligand-based methods, focusing on the structural and physicochemical properties of known ligands to identify new compounds with similar profiles. Several studies integrated machine learning algorithms, such as random forests and neural networks, into virtual screening and docking workflows to enhance predictive accuracy. High-throughput virtual screening strategies were used to rapidly evaluate large compound libraries against target proteins, enabling the identification of potential hits.

Pharmacophore Modelling:

Pharmacophore modelling studies were conducted to elucidate the structural features and interactions required for drug molecules to bind effectively to their targets. These models aided in the rational design of novel drug candidates. Ligand-based pharmacophore modelling studies utilized computational techniques to analyse the common chemical features and spatial arrangements of active ligands in a dataset. These approaches aimed to identify essential pharmacophoric elements for drug design. Structure-based pharmacophore modelling studies incorporated three-dimensional structural information of target proteins or receptor-ligand complexes. These models were employed to elucidate key interactions between ligands and their protein targets.

Pathway Analysis:

Bioinformatics tools were used to unravel complex biological pathways involved in disease processes. These analyses provided insights into potential intervention points and the development of pathway-specific therapeutics. Pathway analysis was instrumental in gaining mechanistic insights into the biological processes involved in diseases. This understanding facilitated the identification of potential drug targets. Enrichment analysis often led to the identification of key pathways associated with specific diseases. These pathways served as focal points for drug discovery efforts. Network-based pathway analysis often incorporated protein-protein interaction data, allowing for the validation and refinement of drug targets within interaction networks. Pathway analysis studies frequently integrated various omics data, including genomics and proteomics, to provide a holistic view of disease mechanisms and potential targets.

Toxicity Prediction:

Several studies explored the prediction of drug toxicity using computational models. These predictive models aimed to reduce the risk of adverse effects during drug development. Bioinformatics-driven toxicity prediction allowed for the early detection of potential toxicological risks associated with drug candidates during the preclinical and early clinical development phases. Predictive models and computational tools contributed to reducing the attrition rates of drug candidates due to unforeseen toxicities, thereby saving time and resources. Structural bioinformatics approaches facilitated SAR analysis, helping identify structural features of compounds associated with toxicity and guiding the design of safer drug candidates. Toxicogenomic studies identified potential biomarkers and molecular signatures associated with drug-induced toxicity, aiding in patient stratification and personalized medicine approaches.

DISCUSSION:

The discovery of pharmacological targets, as well as the screening and refining of potential drug candidates, may be sped up with the use of bioinformatic analysis¹². This kind of study can also ease the characterization of adverse effects and anticipate drug resistance. High-throughput data sets have all made major contributions to mechanism-based drug discovery and drug repurposing¹³. These high-throughput data sets include genomic, epigenetic, genome architecture, cistromic, transcriptomic, and proteomic profiling data¹⁴. The accumulation of protein and RNA structures, as well as the development of homology modelling and protein structure simulation, in conjunction with large structure databases of small molecules and metabolites, paved the way for more realistic protein-ligand docking experiments as well as more informative virtual screening¹⁵. It presents the conceptual framework that drives the collection of these high-throughput data, provides a summary of the utility and potential of mining these data in drug discovery, outlines a few inherent limitations in data and software mining these data, points out new ways to refine analysis of these various types of data, and highlights commonly used software and databases that are relevant to drug discovery¹⁶.

The method of docking tiny molecules into macromolecular structures to determine their binding site scores is known as molecular docking. It is a thriving field of study, with the most alluring instruments being structure-based drug-designing, lead optimization, biochemical route, and drug design. Accurate posture and affinity prediction are two cornerstones of a successful docking attempt. Therefore, it is impossible to make a broad conclusion about the relative merits of different programs with regard to docking precision, ranking precision, or runtime. Furthermore, users don't always think about appropriate variety in their test sets, which causes some systems to outperform others. The primary emphasis has been placed on the difficulties of docking and the troubleshooters in existing programs, the underlying algorithmic background of docking, preferences regarding the use of docking programs for best results illustrated with examples, comparisons of the performance of existing tools and algorithms, the state of the art in docking, recent trends in diseases and current drug industries, evidence from clinical trials, and post-marketing surveillance¹⁷. These concerns and difficulties are at the heart of the debate around the molecular drug design paradigm.

The amount of time and money necessary to produce new medications is cut down significantly thanks to computer-aided drug discovery procedures¹⁸. It is becoming clearer that they are relevant as a result of the increasing prevalence of customized therapy and the demands brought on by unexpected health problems¹⁹. By describing the molecular functional properties required for the binding of a molecule to a certain receptor, pharmacophore techniques constitute one of the most fascinating tools that have been established. These approaches then drive the virtual screening of enormous collections of compounds with the purpose of selecting the compounds that are the most likely to be effective candidates²⁰. There are now accessible computational tools that may be used to develop the pharmacophore model and to carry out virtual screening, both of which have resulted in successful research²¹.

CONCLUSION:

Research & development in the pharmaceutical industry is always striving to improve people's lives by reducing their pain, increasing their longevity, and protecting them from various diseases. For a long time, developing new medicines required a lot of time and effort in the lab, along with the occasional lucky break²². However, the 21^st century has seen a paradigm change, with bioinformatics emerging as a revolutionary force in drug development. This systematic study sets out to investigate the far-reaching effects of bioinformatics on the current state of the pharmaceutical industry. Bioinformatics, a field that combines elements of biology, computer science, mathematics, and informatics, is now widely recognized as an indispensable resource for understanding intricate biological processes^23-27. Within the realm of pharmaceutical research, it provides a methodical, productive, and reasonably priced strategy for figuring out the molecular complexity of illnesses, locating possible therapeutic targets, screening candidate compounds, and enhancing drug development pipelines.

The systematic review addressed a wide variety of topics and approaches related to the use of bioinformatics in the drug development process. Using genomes data to identify possible therapeutic targets was a prominent subject that was investigated^28-31. Among the most important discoveries in this field were those relating to precision medicine, experimental target validation, and medication repurposing. Virtual screening and molecular docking have become indispensable methods for the quick assessment of medication candidates. These structure-based and ligand-based computational methods have completely altered the hit discovery and lead optimization procedures^32-35. Using machine learning methods, we were able to significantly improve predicted accuracy and speed virtual screening. The pharmacophore modelling was also important since it helped to reveal the structural characteristics and interactions necessary for efficient drug-target binding³⁶. This method helped to bridge the gap between computer modelling and experimental validation, which aided the rational creation of innovative drug candidates. Pathway analysis was a crucial bioinformatics method because it revealed important mechanistic insights into disease pathways³⁷. In addition to pinpointing possible pharmacological targets, it helped direct the creation of pathway-specific medicines. In addition, risk assessment relied heavily on toxicity prediction models, which helped reduce the likelihood of unanticipated side effects during medication development³⁸.

Bioinformatics has also become an important driving force in the search for new therapeutics. It has sped up target identification, simplified chemical screening, and improved our knowledge of disease processes³⁹. The delicate balance between biological insights and computational skill continues to guide us as we negotiate the ever-changing environment of bioinformatics in drug discovery, ultimately leading to the creation of novel drugs that hold the potential of enhancing human health and longevity^40-42. Data-driven discoveries and computational advancements together may lead to a better future for medication development.

REFERENCE:

1. Prabhu Manickam Natarajan. Dental Bioinformatics – Current Scope and Future perspectives. Research Journal of Pharmacy and Technology. 2022; 15(5): 2351-6. https://doi.org/10.52711/0974-360X.2022.00391

2. Pragya Chaturvedi, Vijay Laxmi Saxena, Vishakha Raina, Pooran Singh Solanki, Abhishek Chaturvedi. Can Spices Cure Flu?: A Multiple targets based Bioinformatics analysis. Research Journal of Pharmacy and Technology. 2022; 15(11): 4881-6. https://doi.org/10.52711/0974-360X.2022.00820

3. Yamuna M, Elakkiya A. Mathematical Models in Drug Discovery, Development and Treatment of Various Diseases – A Case Study. Research Journal of Pharmacy and Technology. 2017; 10(12): 4397-4401. https://doi.org/10.5958/0974-360X.2017.00810.1

4. Rakhi Mishra, Prem Shankar Mishra, Rupa Mazumder, Avijit Mazumder, Anurag Chaudhary. Computational Docking Technique for Drug Discovery: A Review. Research Journal of Pharmacy and Technology. 2021; 14(10): 5558-2. https://doi.org/10.52711/0974-360X.2021.00968

5. Jeyabaskar Suganya, Sharanya Manoharan, Mahendran Radha, Neha Singh, Astral Francis. Identification and Analysis of Natural Compounds as Fungal Inhibitors from Ocimum sanctum using in silico Virtual Screening and Molecular Docking. Research Journal of Pharmacy and Technology. 2017; 10(10): 3369-3374. https://doi.org/10.5958/0974-360X.2017.00599.6

6. Lohith T N, Lalit Kumar, Ruchi Verma. Design, Molecular Docking, ADME Analysis and Molecular Dynamics Studies of Novel Acetylated Schiff bases as COX-2 inhibitors. Research Journal of Pharmacy and Technology. 2020; 13(4): 1899-1904. https://doi.org/10.5958/0974-360X.2020.00342.X

7. Prachi Parvatikar, Bhaskar Saha, Sayandeep K. Das, R. Chandramouli Reddy, Shrilaxmi Bagali, Raghavendra V. Kulkarni, Aravind V. Patil, Mallanagoud S. Biradar, Kusal K. Das. Molecular Docking Identifies Novel Phytochemical Inhibitors Against SARS-COV-2 for Covid-19 Therapy. Research Journal of Pharmacy and Technology. 2022; 15(2): 555-8. https://doi.org/10.52711/0974-360X.2022.00090

8. Sukesh Kalva, Nikhil Agrawal. Structure based Pharmacophore Modeling and Molecular Docking Studies of Kaposi’s Sarcoma-Associated Herpes Virus (KSHV) Protease – A Therapeutic Drug Target. Research Journal of Pharmacy and Technology. 2019; 12(11): 5177-5181. https://doi.org/10.5958/0974-360X.2019.00896.5

9. Rohan Mishra, Aneesh T P. Combination Vs. Multi-target drugs: The Clash of the titans in the arena of drug discovery; An overview and in silico evaluation. Research Journal of Pharmacy and Technology. 2021; 14(8): 4455-2. https://doi.org/10.52711/0974-360X.2021.00774

10. Anwesha Barua, Keerthi Kesavan, Sivaraman Jayanthi. Molecular Docking Studies of Plant Compounds to Identify Efficient Inhibitors for Ovarian Cancer. Research Journal of Pharmacy and Technology. 2018; 11(9): 3811-3815. https://doi.org/10.5958/0974-360X.2018.00698.4

11. Meenakshi. K N, Sivakumar. M, Srikanth. J. Applications of Molecular docking and virtual screening for Phytoconstituents to identify cognition enhancer activity. Research Journal of Pharmacy and Technology. 2020; 13(9): 4285-4290. https://doi.org/10.5958/0974-360X.2020.00757.X

12. David E., Tramontin T., Zemmel R., Pharmaceutical R. D: the road to positive returns. Natural Review of Drug Discovery. 2009;8:609–610.

13. Sinha KP, Kumar P, Ghosh R. Human Activity Recognition using LSTM with depth data. International Journal of Intelligent Systems and Applications in Engineering. 2023; 11(10s): 535–42. https://www.ijisae.org/index.php/IJISAE/article/view/3309.

14. Sinha KP, Kumar P. Human activity recognition from UAV videos using an optimized hybrid deep learning model. Multimedia Tools and Applications. 2023; http://dx.doi.org/10.1007/s11042-023-17289-3

15. Zien A., Ratsch G., Mika S., Scholkopf B., Lengauer T. Mul- ler, K.R. Engineering support vector machine kernels that recognize translation initiation sites. Bioinformatics. 2000; 16:799–807.

16. Xia X. Bioinformatics and Drug Discovery. Current Topics in Medicinal Chemistry. 2017; 17(15): 1709-1726. https://doi.org/10.2174/1568026617666161116143440.

17. Saikia S, Bordoloi M. Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective. Current Drug Targets. 2019;20(5):501-521. https://doi.org/10.2174/1389450119666181022153016.

18. Sinha KP, Kumar P, Ghosh R. Human Activity Recognition using LSTM with depth data. International Journal of Intelligent Systems and Applications in Engineering. 2023; 11(10s): 535–42. https://www.ijisae.org/index.php/IJISAE/article/view/3309 .

19. Muhammed M.T., Aki-Yalcin E. Homology modeling in drug discovery: Overview, current applications, and future perspectives. Chemical Biology & Drug Design. 2019; 93:12–20. https://doi.org/10.1111/cbdd.13388.

20. Seidel T., Schuetz D.A., Garon A., Langer T. The Pharmacophore Concept and Its Applications in Computer-Aided Drug Design. Progress in the Chemistry of Organic Natural Products. 2019; 110: 99–141.

21. Giordano D, Biancaniello C, Argenio MA, Facchiano A. Drug Design by Pharmacophore and Virtual Screening Approach. Pharmaceuticals (Basel). 2022; May 23; 15(5): 646. https://doi.org/10.3390/ph15050646.

22. Chakravarthi S & Karikalan B. Molecular Biomarkers for Lung Adenocarcinoma: A Short Review. Current Cancer Therapy Reviews. 2020; 16: 1. https://doi.org/10.2174/1573394716666200724164654.

23. Macalino SJ, Gosu V, Hong S, Choi S. Role of computer-aided drug design in modern drug discovery. Archives of Pharmacal Research. 2015; Sep; 38(9): 1686-701. https://doi.org/10.1007/s12272-015-0640-5.

24. Karikalan B & Pasupati T. Lipoleiomyoma of the uterus. Indian Journal of Pathology and Microbiology. 2017; 60(1): 128.

25. Lavecchia A, Di Giovanni C. Virtual screening strategies in drug discovery: a critical review. Current Medicinal Chemistry. 2013; 20(23): 2839-60. https://doi.org/10.2174/09298673113209990001.

26. Karikalan B & Darnal HK. Immune Status of COVID-19 patients with reference to SARS and MERS. Journal of Pure Applied Microbiology. 2020; 14. https://doi.org/10.22207/JPAM.14.SPL1.18. s

27. Malathi K, Ramaiah S. Bioinformatics approaches for new drug discovery: a review. Biotechnology & Genetic Engineering Reviews. 2018 Oct;34(2):243-260 https://doi.org/10.1080/02648725.2018.1502984.

28. Karikalan B & Chakravarthi S. Target Therapy and Immunotherapy for Gastric Cancer-Recent Updates. Current Cancer Therapy Reviews. 2022; 18 (3), 202-208. https://doi.org/10.2174/1573394718666220418095954.

29. Ou-Yang SS, Lu JY, Kong XQ, Liang ZJ, Luo C, Jiang H. Computational drug discovery. Acta Pharmacologica Sinica. 2012; Sep; 33(9): 1131-40. https://doi.org/10.1038/aps.2012.109.

30. Patel L, Shukla T, Huang X, Ussery DW, Wang S. Machine Learning Methods in Drug Discovery. Molecules. 2020; Nov 12; 25(22): 5277. https://doi.org/10.3390/molecules25225277.

31. Ahmed Mahedi MdR, Rawat A, Rabbi F, Babu KS, Tasayco ES, Ore Areche F, Pacovilca-Alejo OV, Corilla Flores DD, Vivanco Aguilar S, L. Orosco F, Syrmos N, Mudhafar M, Afrin S, Rahman MstM. Understanding the Global Transmission and Demographic Distribution of Nipah Virus (NiV). Research Journal of Pharmacy and Technology. 2023; Aug 31; 3588–3594. http://dx.doi.org/10.52711/0974-360x.2023.00592

32. Ahmed Mahedi MdR, Mounich K, Hsu CY, Bhuiyan JR, Jasim IK, Khalaf OM, Darshan JC, Wei CR, Mushfique MB, Syrmos N, Afrin S, Singh P. Cefiderocol (CFDC): A Spy Antibiotic Future Replacement of Carbapenem. Research Journal of Pharmacy and Technology. 2023; 16(11): 5492-6. https://doi.org/10.52711/0974-360X.2023.00888

33. Kannadasan R, Emerson IA, Basha MSS. Docking of HIV-1 with Neem using Autodock in Bioinformatics. Research Journal of Pharmacy and Technology. 2017; 10(11): 3877. Available from: http://dx.doi.org/10.5958/0974-360x.2017.00704.1

34. Chaturvedi P, Laxmi Saxena V, Raina V, Singh Solanki P, Chaturvedi A. Can Spices Cure Flu?: A Multiple targets based Bioinformatics analysis. Research Journal of Pharmacy and Technology. 2022; Nov 24; 4881–4886. Available from: http://dx.doi.org/10.52711/0974-360x.2022.00820

35. Purnama Dewi N, Poddar S, Abdullah D, Teti Vani A. Potential of Pediococcus acidilactici DS1 from Dadiah Bukitinggi as a Tumor Necrosis Factor (TNF) Expression Inhibitor in Bioinformatics. Research Journal of Pharmacy and Technology; 2023; Oct 31; 4737–4740. Available from: http://dx.doi.org/10.52711/0974-360x.2023.00769

36. Arjun S, Venkatesh MP, Balamuralidhara V, Kumar TMP. Expedited programs for Drug Development and Approval in USA. Research Journal of Pharmacy and Technology. 2020; 13(3): 1409. Available from: http://dx.doi.org/10.5958/0974-360x.2020.00258.9

37. D.M R, Basha G S, N. P. Regulatory Strategies for Orphan drug Development in USA–Europe. Research Journal of Pharmacy and Technology. 2021; Jun 29; 3449–3454. Available from: http://dx.doi.org/10.52711/0974-360x.2021.00600

38. Yamuna M, Elakkiya A. Mathematical Models in Drug Discovery, Development and Treatment of Various Diseases-A Case Study. Research Journal of Pharmacy and Technology. 2017; 10(12): 4397. Available from: http://dx.doi.org/10.5958/0974-360x.2017.00810.1

39. Jeganath S, Asha D, Kumar SS, Nair KS, Kumaran KS. Oral Controlled Drug Delivery System-A Review. Research Journal of Pharmacy and Technology. 2018; 11(2): 797. Available from: http://dx.doi.org/10.5958/0974-360x.2018.00151.8

40. Mythili L, Ganesh GNK, Monisha C, Kayalvizhi R. Ocular Drug Delivery System-An Update Review. Research Journal of Pharmacy and Technology. 2019; 12(5): 2527. Available from: http://dx.doi.org/10.5958/0974-360x.2019.00426.8

41. Jamali M, Islam SMS, Bhuiyan JR, Wei CR, Afrin S, Singh P, Musarrat Z, Rajbongshi P, Timothy Singh, Mahedi RA, Syrmos N, Guia LC. Exploring the intricacies of encephalitis in mosquito-borne diseases through vector-host-pathogen interactions: A critical review. Journal of Clinical Medical Research. 2023; 1–10. http://dx.doi.org/10.46889/jcmr.2023.4312

42. Mahedi MRA, Afrin S, Wei CR, Bhuiyan JR, Paul S, Syrmos N, Orosco F. AI-Driven Drug Development in Pharmaceutical Industry. Beyond Boundaries: Exploring The Synergies of Interdisciplinary Research. CIRS Publication. 2023; 213 – 250. https://doi.org/10.5281/zenodo.10465506

Received on 23.01.2024 Revised on 15.07.2024

Accepted on 08.11.2024 Published on 24.12.2024

Available online from December 27, 2024

Research J. Pharmacy and Technology. 2024;17(12):6158-6164.

DOI: 10.52711/0974-360X.2024.00934